ncRNA basic information
ncRNA ID:
NA
ncRNA Database:
miRBase
ncRNA Name:
miR-19b-5p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
KRAS
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
In our study, these results demonstrated that microRNA-19b-5p was significantly downregulated in 37 pairs of nasopharyngeal carcinoma tissues when compared to normal tissues. Enforced expression of microRNA-19b-5p inhibited activity of cell proliferation and cell migration of nasopharyngeal carcinoma cancer cells, CNE1 and HNE1. Furthermore, microRNA-19b-5p targeted KRAS proto-oncogene, GTPase in cancer cells. In human clinical specimens, KRAS was higher expressed in cancer tissues when compared with normal tissues, which was inversely correlated with the expression of microRNA-19b-5p. More interestingly, microRNA-19b-5p sensitizes CNE1 cells to cisplatin by inhibiting its target KRAS. Finally, microRNA-19b-5p inhibits tumorigenesis in vivo. Thus, our results investigated that microRNA-19b-5p functioned as a tumor suppressor and indicated its potential application for the treatment of human nasopharyngeal carcinoma in future.
Drug Response:
sensitive
Cancer basic information
Cancer:
Nasopharyngeal Carcinoma
Tissue/Cell:
cell line ( HEK293T )
Other information
Title:
MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS.
Journal:
Technol Cancer Res Treat
Published:
2018
PubMed ID:
30231694